Annual EBITDA
-$210.51 M
-$82.99 M-65.08%
December 31, 2023
Summary
- As of February 8, 2025, XENE annual EBITDA is -$210.51 million, with the most recent change of -$82.99 million (-65.08%) on December 31, 2023.
- During the last 3 years, XENE annual EBITDA has fallen by -$182.55 million (-652.75%).
- XENE annual EBITDA is now -1744.50% below its all-time high of $12.80 million, reached on December 31, 2013.
Performance
XENE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$73.68 M
-$5.23 M-7.64%
September 30, 2024
Summary
- As of February 8, 2025, XENE quarterly EBITDA is -$73.68 million, with the most recent change of -$5.23 million (-7.64%) on September 30, 2024.
- Over the past year, XENE quarterly EBITDA has dropped by -$5.23 million (-7.64%).
- XENE quarterly EBITDA is now -933.06% below its all-time high of $8.84 million, reached on September 30, 2014.
Performance
XENE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$253.41 M
-$19.73 M-8.44%
September 30, 2024
Summary
- As of February 8, 2025, XENE TTM EBITDA is -$253.41 million, with the most recent change of -$19.73 million (-8.44%) on September 30, 2024.
- Over the past year, XENE TTM EBITDA has dropped by -$19.73 million (-8.44%).
- XENE TTM EBITDA is now -1872.08% below its all-time high of $14.30 million, reached on September 30, 2014.
Performance
XENE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XENE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.1% | -7.6% | -8.4% |
| 3 y3 years | -652.8% | -33.9% | -37.5% |
| 5 y5 years | -546.9% | -33.9% | -37.5% |
XENE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -169.6% | at low | -333.6% | at low | -224.5% | at low |
| 5 y | 5-year | -652.8% | at low | <-9999.0% | at low | -865.0% | at low |
| alltime | all time | -1744.5% | at low | -933.1% | at low | -1872.1% | at low |
Xenon Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$73.68 M(+7.6%) | -$253.41 M(+8.4%) |
| Jun 2024 | - | -$68.44 M(+17.1%) | -$233.68 M(+6.1%) |
| Mar 2024 | - | -$58.44 M(+10.6%) | -$220.26 M(+4.6%) |
| Dec 2023 | -$210.51 M(+65.1%) | -$52.84 M(-2.1%) | -$210.51 M(+5.0%) |
| Sep 2023 | - | -$53.95 M(-1.9%) | -$200.49 M(+8.8%) |
| Jun 2023 | - | -$55.02 M(+13.0%) | -$184.31 M(+15.8%) |
| Mar 2023 | - | -$48.70 M(+13.7%) | -$159.22 M(+24.9%) |
| Dec 2022 | -$127.52 M(+63.3%) | -$42.82 M(+13.4%) | -$127.52 M(+16.7%) |
| Sep 2022 | - | -$37.77 M(+26.2%) | -$109.27 M(+25.8%) |
| Jun 2022 | - | -$29.94 M(+76.2%) | -$86.89 M(+9.7%) |
| Mar 2022 | - | -$16.99 M(-30.8%) | -$79.22 M(+1.4%) |
| Dec 2021 | -$78.09 M(+179.2%) | -$24.57 M(+59.6%) | -$78.09 M(+18.9%) |
| Sep 2021 | - | -$15.39 M(-30.9%) | -$65.65 M(+11.0%) |
| Jun 2021 | - | -$22.27 M(+40.4%) | -$59.15 M(+60.8%) |
| Mar 2021 | - | -$15.86 M(+30.7%) | -$36.78 M(+31.5%) |
| Dec 2020 | -$27.97 M(-29.7%) | -$12.13 M(+36.5%) | -$27.97 M(+4.5%) |
| Sep 2020 | - | -$8.89 M(-8405.6%) | -$26.75 M(+1.9%) |
| Jun 2020 | - | $107.00 K(-101.5%) | -$26.26 M(-26.9%) |
| Mar 2020 | - | -$7.05 M(-35.4%) | -$35.94 M(-9.6%) |
| Dec 2019 | -$39.76 M(+22.2%) | -$10.92 M(+30.0%) | -$39.76 M(+7.7%) |
| Sep 2019 | - | -$8.40 M(-12.2%) | -$36.92 M(-12.3%) |
| Jun 2019 | - | -$9.57 M(-11.9%) | -$42.09 M(+5.3%) |
| Mar 2019 | - | -$10.87 M(+34.5%) | -$39.97 M(+22.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$32.54 M(+8.3%) | -$8.08 M(-40.5%) | -$32.54 M(+0.5%) |
| Sep 2018 | - | -$13.57 M(+82.0%) | -$32.38 M(+22.7%) |
| Jun 2018 | - | -$7.46 M(+117.2%) | -$26.38 M(-1.0%) |
| Mar 2018 | - | -$3.43 M(-56.6%) | -$26.65 M(-14.1%) |
| Dec 2017 | -$30.05 M(+25.5%) | -$7.92 M(+4.5%) | -$31.04 M(+9.2%) |
| Sep 2017 | - | -$7.57 M(-1.9%) | -$28.42 M(+1.5%) |
| Jun 2017 | - | -$7.72 M(-1.3%) | -$28.01 M(+6.1%) |
| Mar 2017 | - | -$7.82 M(+47.7%) | -$26.40 M(+10.2%) |
| Dec 2016 | -$23.95 M(+187.8%) | -$5.30 M(-26.1%) | -$23.95 M(+14.2%) |
| Sep 2016 | - | -$7.16 M(+17.1%) | -$20.98 M(+46.0%) |
| Jun 2016 | - | -$6.12 M(+13.8%) | -$14.37 M(+85.0%) |
| Mar 2016 | - | -$5.38 M(+131.8%) | -$7.77 M(-6.7%) |
| Dec 2015 | -$8.32 M(-170.3%) | -$2.32 M(+315.6%) | -$8.32 M(+44.4%) |
| Sep 2015 | - | -$558.00 K(-215.3%) | -$5.76 M(-258.4%) |
| Jun 2015 | - | $484.00 K(-108.2%) | $3.64 M(-22.7%) |
| Mar 2015 | - | -$5.93 M(-2570.8%) | $4.71 M(-60.3%) |
| Dec 2014 | $11.84 M(-7.5%) | $240.00 K(-97.3%) | $11.84 M(-17.2%) |
| Sep 2014 | - | $8.84 M(+469.5%) | $14.30 M(+19.1%) |
| Jun 2014 | - | $1.55 M(+28.7%) | $12.01 M(+14.9%) |
| Mar 2014 | - | $1.21 M(-55.2%) | $10.46 M(+13.1%) |
| Dec 2013 | $12.80 M(-474.1%) | $2.70 M(-58.9%) | $9.25 M(+41.1%) |
| Sep 2013 | - | $6.55 M | $6.55 M |
| Dec 2012 | -$3.42 M(-68.2%) | - | - |
| Dec 2011 | -$10.77 M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual EBITDA year-on-year change?
- What is Xenon Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Xenon Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM EBITDA year-on-year change?
What is Xenon Pharmaceuticals annual EBITDA?
The current annual EBITDA of XENE is -$210.51 M
What is the all time high annual EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual EBITDA is $12.80 M
What is Xenon Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, XENE annual EBITDA has changed by -$82.99 M (-65.08%)
What is Xenon Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of XENE is -$73.68 M
What is the all time high quarterly EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly EBITDA is $8.84 M
What is Xenon Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, XENE quarterly EBITDA has changed by -$5.23 M (-7.64%)
What is Xenon Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of XENE is -$253.41 M
What is the all time high TTM EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM EBITDA is $14.30 M
What is Xenon Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, XENE TTM EBITDA has changed by -$19.73 M (-8.44%)